Financial Ratios

BAL PHARMA LTD.

NSE : BALPHARMABSE : 524824ISIN CODE : INE083D01012Industry : Pharmaceuticals & DrugsHouse : Private
BSE100.88-0.2 (-0.2 %)
PREV CLOSE ( ) 101.08
OPEN PRICE ( ) 102.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 935
TODAY'S LOW / HIGH ( )100.88 102.20
52 WK LOW / HIGH ( )71 132.2
NSE100.60-0.65 (-0.64 %)
PREV CLOSE( ) 101.25
OPEN PRICE ( ) 101.00
BID PRICE (QTY) 100.60 (52)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6289
TODAY'S LOW / HIGH( ) 100.00 103.95
52 WK LOW / HIGH ( )77.5 132.45
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)3.905.796.14-6.284.77
   CEPS(Rs)8.6710.6711.03-1.329.08
   DPS(Rs)1.001.001.000.001.00
   Book NAV/Share(Rs)60.3257.6652.8846.5354.23
   Tax Rate(%)28.3428.847.141.92-53.27
Margin Ratios
   Core EBITDA Margin(%)8.638.3610.634.119.18
   EBIT Margin(%)6.878.088.802.127.67
   Pre Tax Margin(%)2.824.303.93-5.321.98
   PAT Margin (%)2.023.063.65-5.223.03
   Cash Profit Margin (%)4.495.646.56-1.105.77
Performance Ratios
   ROA(%)1.923.113.63-3.592.66
   ROE(%)6.8010.4712.61-12.479.07
   ROCE(%)10.2512.2812.572.099.95
   Asset Turnover(x)0.951.021.000.690.88
   Sales/Fixed Asset(x)3.043.152.962.153.02
   Working Capital/Sales(x)5.245.385.385.934.91
Efficiency Ratios
   Fixed Capital/Sales(x)0.330.320.340.460.33
   Receivable days104.0195.9188.65125.48106.15
   Inventory Days103.3687.2993.46146.56111.00
   Payable days190.52144.48114.32209.22171.49
Valuation Parameters
   PER(x)17.1418.638.760.0014.78
   PCE(x)7.7210.114.87-24.607.76
   Price/Book(x)1.111.871.020.701.30
   Yield(%)1.490.931.860.001.42
   EV/Net Sales(x)0.740.900.720.840.90
   EV/Core EBITDA(x)7.878.466.1713.408.62
   EV/EBIT(x)10.7011.168.2139.4211.70
   EV/CE(x)0.640.870.690.600.78
   M Cap / Sales0.350.570.320.270.45
Growth Ratio
   Net Sales Growth(%)8.1112.4646.07-23.497.43
   Core EBITDA Growth(%)-5.282.39174.27-54.18-5.45
   EBIT Growth(%)-8.053.27506.36-78.86-4.06
   PAT Growth(%)-28.59-5.69202.19-231.6913.84
   EPS Growth(%)-32.54-5.69197.71-231.6913.84
Financial Stability Ratios
   Total Debt/Equity(x)1.321.151.331.511.36
   Current Ratio(x)1.271.311.321.211.32
   Quick Ratio(x)0.810.870.910.730.85
   Interest Cover(x)1.702.141.810.291.35
   Total Debt/Mcap(x)1.190.611.312.161.05

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.